Topics

Senior Vice President, Market Development, at ConnectiveRx.

Articles

The key strategies for reducing or eliminating post-prescription abandonment.

From Prescription to Patient: Four Ways to Increase Speed to Therapy 

A look at the prevailing factors impacting treatment access in 2025.

Healthcare Scorecard from Patients with Chronic Illness

How pharma manufacturers can steadily navigate GTN components and                                             complexities when planning pharmacy benefit reimbursement.

Popping the Gross-to-Net Bubble, Part III: The Pharmacy Benefit

Respective industry and government agendas could significantly reshape the US prescription drug market.

US Drug Price Negotiations and Transparency

. He can be reached at nsaraceno@mjhlifesciences.com.

Videos

In the first part of his video interview with Pharma Commerce Editor Nicholas Saraceno, Chris O’Dell, Turquoise Health’s SVP of market solutions, outlines the key provisions of the recently released executive order on healthcare price transparency.

Breaking Down the New Executive Order on Healthcare Price Transparency

How data-driven insights can help pharma companies balance their revenue management and innovation strategies—including resource allocation, pricing, and market access.

Maintaining R&D Investments in the IRA Era

Jen Butler, chief commercial officer, Pleio, discusses how the company’s GoodStart programs help patients navigate specialty pharmacies. 

Hubs East 2025: Navigating Specialty Medication Onboarding

Jonathan James, CEO, Hope Charities, discusses how, despite policy advancements, millions of people still face barriers to healthcare access.

PAP 2025: The Unfinished Work of Healthcare Reform

A roundtable explores how patient access needs are being measured, while also discussing the value of affordability in decision-making. 

Access USA 2025: Uncovering Patient Access Complexities

The partnership focuses on enhancing the patient experience by providing greater affordability and access to specialty meds.

Market Access